Cadre (CDRE) Competitors $32.42 -0.07 (-0.22%) Closing price 03:59 PM EasternExtended Trading$32.48 +0.07 (+0.21%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDRE vs. TMDX, SLNO, NVST, LIVN, INSP, WRBY, LQDA, PRCT, LMAT, and AORTShould you be buying Cadre stock or one of its competitors? The main competitors of Cadre include TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Inspire Medical Systems (INSP), Warby Parker (WRBY), Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), and Artivion (AORT). These companies are all part of the "medical equipment" industry. Cadre vs. Its Competitors TransMedics Group Soleno Therapeutics Envista LivaNova Inspire Medical Systems Warby Parker Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion TransMedics Group (NASDAQ:TMDX) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment. Is TMDX or CDRE more profitable? TransMedics Group has a net margin of 13.49% compared to Cadre's net margin of 6.65%. TransMedics Group's return on equity of 28.02% beat Cadre's return on equity.Company Net Margins Return on Equity Return on Assets TransMedics Group13.49% 28.02% 8.64% Cadre 6.65%12.08%5.60% Do analysts recommend TMDX or CDRE? TransMedics Group presently has a consensus target price of $122.11, suggesting a potential upside of 6.58%. Cadre has a consensus target price of $31.50, suggesting a potential downside of 2.83%. Given TransMedics Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe TransMedics Group is more favorable than Cadre.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70Cadre 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals hold more shares of TMDX or CDRE? 99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 7.0% of TransMedics Group shares are held by insiders. Comparatively, 31.5% of Cadre shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings & valuation, TMDX or CDRE? Cadre has higher revenue and earnings than TransMedics Group. Cadre is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransMedics Group$441.54M8.85$35.46M$1.9359.36Cadre$567.56M2.32$36.13M$0.9434.49 Does the media prefer TMDX or CDRE? In the previous week, Cadre had 3 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Cadre and 8 mentions for TransMedics Group. Cadre's average media sentiment score of 1.35 beat TransMedics Group's score of 0.86 indicating that Cadre is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadre 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, TMDX or CDRE? TransMedics Group has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. SummaryTransMedics Group beats Cadre on 12 of the 17 factors compared between the two stocks. Get Cadre News Delivered to You Automatically Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDRE vs. The Competition Export to ExcelMetricCadrePROTECTION IndustryIndustrials SectorNYSE ExchangeMarket Cap$1.32B$2.29B$7.76B$21.69BDividend Yield1.17%1.79%4.56%3.47%P/E Ratio34.4921.20315.1229.69Price / Sales2.325.24215.3751.97Price / Cash22.9478.0628.9125.00Price / Book4.2312.354.604.58Net Income$36.13M$109.95M$798.53M$1.00B7 Day Performance1.45%4.32%0.96%0.66%1 Month Performance9.25%5.14%1.30%4.64%1 Year Performance-7.46%46.63%27.14%15.96% Cadre Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDRECadre2.8464 of 5 stars$32.42-0.2%$31.50-2.8%-5.7%$1.32B$567.56M34.492,284Positive NewsTMDXTransMedics Group2.8578 of 5 stars$114.96-1.5%$123.00+7.0%-18.6%$3.92B$441.54M59.57210SLNOSoleno Therapeutics4.4347 of 5 stars$67.67-1.1%$115.09+70.1%+16.8%$3.60BN/A-16.3530Trending NewsAnalyst UpgradeShort Interest ↑Analyst RevisionNVSTEnvista3.9232 of 5 stars$21.15-0.5%$20.92-1.0%+22.5%$3.52B$2.51B66.0812,300Positive NewsLIVNLivaNova2.9039 of 5 stars$56.37+1.7%$59.71+5.9%+20.8%$3.08B$1.25B-14.492,900Positive NewsINSPInspire Medical Systems4.9005 of 5 stars$93.86+2.6%$165.62+76.4%-60.0%$2.77B$802.80M54.261,246Positive NewsWRBYWarby Parker1.6853 of 5 stars$26.16-0.3%$24.06-8.0%+96.3%$2.76B$771.32M-373.723,780Positive NewsInsider TradeLQDALiquidia Technologies3.7 of 5 stars$27.68+0.8%$32.11+16.0%+166.0%$2.38B$14M-16.2850Positive NewsPRCTPROCEPT BioRobotics3.2237 of 5 stars$40.17-0.4%$74.88+86.4%-50.5%$2.23B$224.50M-25.92430Positive NewsLMATLeMaitre Vascular3.0875 of 5 stars$95.36+0.1%$97.60+2.3%+8.6%$2.16B$219.86M46.29490Positive NewsAORTArtivion3.0785 of 5 stars$43.87+0.1%$40.63-7.4%+73.7%$2.07B$388.54M-104.451,600Positive News Related Companies and Tools Related Companies TMDX Alternatives SLNO Alternatives NVST Alternatives LIVN Alternatives INSP Alternatives WRBY Alternatives LQDA Alternatives PRCT Alternatives LMAT Alternatives AORT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CDRE) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadre Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadre With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
